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Introduction
Cytochrome P450 2D6 (CYP2D6) encodes an enzyme clinically relevant to the use of tamoxifen (Goetz et al., 2005; Goetz et al., 2007) and the selection of psychiatric drugs (Black 3rd et al., 2007) . CYP2D6 testing is sometimes done before tamoxifen treatment of breast cancer because patients who fail to metabolize tamoxifen to endoxifen via the CYP2D6 pathway may be at increased risk of breast cancer relapse (Goetz et al., 2007) . Genotyping is also used to select psychotropic medications (Topic et al., 2000; Murphy et al., 2003; Kirchheiner et al., 2004; Malhotra et al., 2004) .
The CYP2D locus contains the CYP2D8 and CYP2D7 pseudogenes 5' to the CYP2D6 gene ( Figure 1A ). CYP2D6 genetic complexity is due to single nucleotide polymorphisms (SNPs), polymorphisms. All samples originally genotyped with the v1 kits which contained a CYP2D6*2 allele with duplication were retested using the v2 kit in order to identify CYP2D6*41 alleles. The 138insT and 1758G>A have a very low frequency, as we have found 4 and 2 alleles, respectively in our experience of over 11,000 samples so we did not retest our samples for these.
The 1661G>C and 4180G>C polymorphisms are part of several alleles and were added to the CYP2D6 ASPE kit v2 to help confirm allelic calls so retesting for these was not done. In 240 of 285 heterozygous duplication samples, the duplicated allele was predicted on the basis of the mutant allelic ratios as established for the clinical assay.
Analysis Software version 6.71 (Molecular Biology Insights Inc., Cascade, Colorado, USA).
PCR amplicon locations are shown in Figure 1 and 2 as black bars under each structure. Specific primers were designed to prevent unintentional nonspecific annealing between the CYP2D6 gene, CYP2D7 pseudogene and CYP2D8 pseudogene. All samples were screened for CYP2D6-2D7 genes using amplicon E and CYP2D7-2D6 genes using amplicon G regardless of the original genotype.
The PCR master mix was composed of 12 µL reactions containing 0.12 µL TaKaRa LA Taq Amplicons A-E, G, and J (Table 1) were generated as described by Kramer et al (Kramer et al., 2009 ). Thermocycler parameters for amplicon K were as follows: 94°C for 1 minute followed by 96°C for 10 seconds, 64°C for 30 seconds, 68°C for 11 minutes for 30 cycles and a final extension at 72°C for 10 min and a 4°C hold. Thermocycler parameters for fragment L were: 94°C for 1 minute followed by 35 cycles of 96°C for 10 seconds and 68°C for 4 minutes, a final extension at 72°C for 10 min and a 4°C hold. Thermocycler parameters for fragment M and N were: 94°C for 1 minute followed by 30 cycles of 96°C for 10 seconds and 68°C for 9 minutes, a final extension at 72°C for 10 min and a 4°C hold.
PCR fragment sizes were analyzed using the Agilent Technologies DNA 12000 Kit (Agilent Technologies, Waldbronn, Germany) as per manufacturer's protocol. Expected fragment sizes are shown in Table 1 .
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Genotyping by allele-specific primer extension assay
Genotyping of amplicons A-E, G, and J-M (Table 1) was performed using the Luminex Tag-It Mutation Detection Kit for Cytochrome P450-2D6 version 2 (CYP2D6 ASPE kit) (Austin, Texas, USA) as described in the product literature but without the original amplification step using the A and B primer sets. All samples were analyzed on the Luminex 100 IS device using IS 2.3 software (Austin, Texas, USA).
DNA sequencing
DNA sequencing was performed using an Applied Biosystems 3730xl DNA Analyzer and the ABI PRISM dRhoamine Terminator Cycle Sequencing Ready Reaction Kit with AmpliTaq DNA Polymerase, FS. All CYP2D7-2D6 genes (amplicon G) and their associated rep dup regions (amplicon L) were sequenced bidirectionally using multiple overlapping amplicons. In addition, a unique structure containing a CYP2D6*13B + *68 X 2 + *4-like was discovered (described below) and was sequenced from exon 9 of CYP2D6*13B through exon 9 of CYP2D6*68 using amplicons E, G and K. Source of DNA for all sequencing was genomic DNA isolated from blood and amplicons were generated per PCR section noted previously.
Real Time PCR CYP2D6 copy number assays
The CYP2D6 copy number in samples containing both a CYP2D7-2D6 gene and a duplication signal was determined using two real time PCR (rtPCR) assays which targeted different regions of the gene (Figure 1 and 2). This assay was done only on the duplication samples because accurate copy number determination was needed to predict phenotype. Phenotype prediction for CYP2D6*4 and CYP2D6*10 containing samples is not impacted by copy number as will be discussed below so copy number was not determined for these samples. One assay,
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This article has not been copyedited and formatted. The final version may differ from this version. City, CA). The other assay targeted the 5'-flanking region as described by Hosono et al (Hosono et al., 2009 ) was synthesized and purchased from ABI. Both assays were performed in triplicate with an internal control-RNaseP TaqMan® copy number reference and TaqMan® Genotyping PCR Master Mix on a StepOne Plus rtPCR instrument as directed by the manufacturer (ABI).
Relative quantification was performed using CopyCaller® Software (ABI) following the comparative Δ Δ C T method. The confidence estimate for a given sample was automatically generated. It is the probability that the calculated copy number is the correct assignment compared to other copy numbers that have nonzero probability of occurring. (Kirchheiner et al., 2004) .
It should be noted that other methodologies for phenotype prediction have been described and this is a controversial area of pharmacogenomics (Steimer et al., 2004; Gaedigk et al., 2008 Of samples homozygous for any allele (N=332), 4 (1.2%) had a CYP2D7-2D6 gene. Of samples with a duplication signal (N=341), 25 (7.3%) contained a CYP2D7-2D6 + CYP2D6 hybrid tandem or similar arrangement as discussed below. Tandem   Table 3 shows the actual 5' genes present in the CYP2D7-2D6 + CYP2D6 hybrid tandems we observed. DNA sequence analysis was done for all of the 5' genes found in this research. In 7 samples the DNA sequence analysis revealed that the 5' gene was actually a CYP2D7 which converted to a CYP2D6 sequence in the 0.6kb repeat located just downstream of the CYP2D7 were observed.
Characteristics of 5' Genes in CYP2D7-2D6 + CYP2D6 Hybrid
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based upon sequence data and comparison to CYP2D7 and CYP2D6 sequence data although it also contains one CYP2D7-like SNP in exon 8.
To confirm the presence of a rep dup in each of these samples, DNA sequence analysis was performed using amplicon L (Table 1 , Figure 1B and 2B-D). In every case, the first 53 nucleotides of rep dup contained the five nucleotides specific to rep 6 and the last 39 nucleotides of rep dup contained the four nucleotides that define rep 7 (Steen et al., 1995; Soyama et al., 2006) . Absence of the CYP2D7 pseudogene 5' to all CYP2D7-2D6 hybrids was confirmed by the presence and size of fragment J ( Figure 2B -2E) which cannot be generated if CYP2D7 is present due to the size of the amplicon. found to have a tandem hybrid. While these numbers are small, the risk of an undetected hybrid tandem being present in a sample appears to be greatest in those samples where the CYP2D6*1, CYP2D6*2A, CYP2D6*4 and CYP2D6*41 is predicted to be duplicated using the CYP2D6 ASPE kits as described here.
Characteristics of Single CYP2D7-2D6 Genes
DNA sequencing was performed on all homozygous samples which were found to contain a single CYP2D7-2D6 gene ( Figure 2A ). Of these, 3 were found to be a CYP2D6*13F and one was found to have a novel allele named CYP2D6*13G1 (JN618990). (Table 3) The CYP2D6 copy number was determined for all samples that gave a duplication signal and were determined to have a CYP2D7-2D6 + CYP2D6 arrangement. Real time PCR (rtPCR) assays were performed which used one primer pair plus a Taqman® probe to target the intron 6 region of CYP2D6 and another primer pair plus Taqman® probe to target the 5' flanking region of the CYP2D6 promoter region (Figure 1 and 2). CYP2D7-2D6 genes were detected on the basis that the copy number varied between the two regions. Specifically, CYP2D7-2D6 genes have a CYP2D7 promoter region so the 5' flanking probe will not bind there in distinction to any CYP2D6 genes present in a sample. CYP2D7-2D6 genes that switch to CYP2D6 sequence upstream of intron 6 have a binding site for the intron 6 probe. Therefore, early crossing CYP2D7-2D6 genes (e.g. CYP2D6*13A1, CYP2D6*13A1 variant 1 and variant 2, CYP2D6*13A2, CYP2D6*13D, CYP2D6*13B) which convert to CYP2D6 sequence upstream of intron 6 were detected with the intron 6 probe but not by the 5' CYP2D6 probe. The CYP2D7-
Gene Copy Numbers of CYP2D7-2D6 + CYP2D6 Hybrid Tandems
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promotor assay, respectively, suggesting 2 copies of CYP2D6*68. Cases 15 and 19 are discussed in detail below.
Novel CYP2D7-2D6 + CYP2D6 X N Hybrid Tandem
We could not reliably determine the number of CYP2D6 genes by rtPCR in case 15 (Table 3) .
We expected that the intron 6 assay would show one more copy than the CYP2D6 promoter assay, since the CYP2D6*13A1 gene would not be detected by the Taqman® probe in the promoter region. The presumed reason for this finding is that reliability of rtPCR to detect copy numbers higher than 5 is poor (see product literature). The structure of this sample was supported by CYP2D6 ASPE kit analysis of fragments A and B (Table 1, Figure 2D ), both of which were genotyped as CYP2D6*1. This is the first time that a CYP2D7-2D6 hybrid gene has been reported as part of a multiplied CYP2D6 arrangement.
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The results from PCR fragment analysis (Figure 3) , CYP2D6 ASPE kit, sequence analysis (amplicons E, G and K), and copy number assays were compiled to generate the structure of case 19 (Table 3 , Figure 2E ), a novel CYP2D7-2D6 + CYP2D6-2D7 X 2 + CYP2D6 hybrid tandem.
The presence of CYP2D6*13B followed by CYP2D6*68 on the same chromosome was confirmed by the amplification of fragment K (Figure 3 , lane 7) which spans from exon 9 in CYP2D6 to exon 9 in CYP2D7. This amplicon was sequenced using multiple amplicons and primers to ensure continuity between the CYP2D6*13B and CYP2D6*68 alleles. In addition, four copies of the CYP2D6 promoter region were observed with the rtPCR CYP2D6 promoter copy number assay, consistent with two CYP2D6*68 alleles plus CYP2D6*4 on one chromosome and CYP2D6*1 on the other chromosome. Whereas, 3 copies of CYP2D6 intron 6
were found using the intron 6 copy number assay. This is because CYP2D6*13B contains CYP2D6 intron 6 as does CYP2D6*4 on the same chromosome and CYP2D6*1 on the other chromosome but CYP2D6*68, which converts to CYP2D7 in intron 1, is not detected by the intron 6 copy number assay. The presence of tandem CYP2D6*68 alleles was confirmed by PCR amplification using forward primers located in the rep 7 (fragment M) and rep 6 (fragment N) regions of the gene with a reverse primer located in exon 9 of CYP2D7 (Figure 3 , lane 10).
These amplifications would occur only if both rep dup and rep 7 each were followed by a CYP2D6*68 (CYP2D6-2D7) arrangement (see Figure 2E ). Original genotyping of case number 19 yielded a CYP2D6*1/*4 genotype. This genotype is consistent with the arrangement shown in Figure 2E because the locations of the Luminex kit primers allows PCR amplification of both the normal CYP2D6 ( Figure 1A ) as well as the 3' most CYP2D6 structure in the novel arrangement ( Figure 2E ). It should be noted that although CYP2D6*13B has been observed
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Impact of Hybrid Genes on Predicted Phenotype
CYP2D6-CYP2D7 + CYP2D6 Hybrid Tandems
The CYP2D6*4, CYP2D6*4N, and CYP2D6*4-like alleles have the 1846A variation which results in a splicing defect which encodes an enzyme with no activity. The CYP2D6*68 converts to CYP2D7 sequence from intron 1 forward and is also expected to produce a null allele due to the presence of the CYP2D6*10 polymorphism c.100C>T plus the presence of an exon 4 c.631dupG resulting in a frame shift causing a stop codon 43 bases downstream on the insertion (p.Glu211GlyfsX43) although no in vivo or in vitro research has been reported for this allele.
The CYP2D6*10 allele is described as having reduced function and the CYP2D6*36 allele is described as having poor function (Gaedigk et al., 2006) . Thus, the presence of a CYP2D6*36, *4N, and *68 in a tandem does not impact the predicted phenotype of the sample.
Single CYP2D7-2D6 Samples All CYP2D7-2D6 genes carry a T-insertion in exon 1 that causes a frameshift and a premature termination (c.137_138insT, p.Leu47AlafsX207). These hybrids are nonfunctional (Gaedigk et al., 2010b) . Four (100%) of 4 samples originally genotyped as having a homozygous genotype which were found to have a CYP2D7-2D6 gene on one chromosome ( Figure 2A ) had a change in phenotype prediction. These samples were originally genotyped as CYP2D6*1/*1 but were found to actually be heterozygous for CYP2D6*13G1 (N=1) and CYP2D6*13F (N=3) resulting in a change in phenotype prediction from EM to IM.
CYP2D7-2D6 + CYP2D6 Hybrid Tandem
DMD #40832
This article has not been copyedited and formatted. The final version may differ from this version. Table 3 shows the change in phenotype of the samples with CYP2D7-2D6 + CYP2D6 hybrid tandems ( Figure 2B and 2C) observed in this research. Detection of the hybrid gene resulted in a change of predicted phenotype in 23 (92%) of 25 samples containing a hybrid. In 9 of the samples (cases 4, 11, 13, 14, 19, 20, 22, 24 and 25) , the duplicated allele could not be predicted at the time of original genotyping and the original phenotype was specified "EM or IM". After the correct genotype was determined, the predicted phenotype was confirmed to be IM. Thus, in these cases, more precise phenotype prediction could be determined using the methods described here. If these 5 cases are also included in the "no change" group, then 18 samples (56%) had a change in phenotype.
Discussion
The intent of this study was to determine the frequency of CYP2D6-2D7 and CYP2D7-2D6 genes in samples containing CYP2D6*4 alleles, CYP2D6*10 alleles, homozygous samples of any variety and samples with duplication signals that were originally genotyped with a commercially available ASPE kit. Furthermore, we wanted to determine the impact of these undetected genes on predicted phenotype.
The main findings of this research are that hybrid genes: 1) are relatively common in clinical samples containing CYP2D6*4 alleles, CYP2D6*10 alleles, and duplication signals, 2) are uncommon in homozygous samples, and 3) frequently impact phenotype prediction in samples originally genotyped as homozygous and, separately, those that were originally genotyped as having a duplication. However, hybrid tandems do not change predicted phenotype in CYP2D6*4 and CYP2D6*10-containing samples.
Our results involving duplication samples supports those described by Gaedigk et al (Gaedigk et al., 2010a) in which three CYP2D6*13A2 + *2 and one CYP2D6*13D + *2 were found in 32
This article has not been copyedited and formatted. The final version may differ from this version. Interestingly, no hybrid genes were observed with other CYP2D6*2 variants. We also identified seven samples with duplication signals which contained a CYP2D7 gene with a CYP2D6-like region downstream of exon 9 similar to that described by Gaedigk et al (Gaedigk et al., 2010b) .
Specifically, cases 1, 10, 20, and 22 had a CYP2D7 + *1, cases 4 and 16 had a CYP2D7 + *41, and case 8 had a CYP2D7 + *4 and all had sequence confirmed rep dup 3' to the CYP2D7 hybrid allele.
In our collection of 341 samples originally genotyped with duplications, a hybrid tandem gene was present in 25 (7.3%) and this had an impact upon phenotype prediction on 92% of these samples. Furthermore, the presence of a single CYP2D7-2D6 gene was only found in 4 of 332 samples originally genotyped as homozygous but it changed predicted phenotype in 100% of cases. Although the need to test for the rare single CYP2D7-2D6 gene in a clinical setting can be debated in the absence of actual evidence that a given patient has genotype-phenotype discordance, the authors argue that the frequency of hybrid tandems in duplication samples and their impact on phenotype prediction warrants their analysis.
The CYP2D6 ASPE kit that was used to originally genotype our samples was not designed to detect hybrid genes thus it is not surprising that none were detected by this kit during original clinical genotyping. Hybrid genes will not be detected in a sequence-based analysis either unless primers are designed to specifically allow for the PCR amplification of these hybrids.
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Conclusions
CYP2D7-2D6 genes must be specifically tested for using methods comparable to those outlined here in order to be detected. CYP2D7-2D6 genes were found frequently in samples originally genotyped to have duplications using a CYP2D6 ASPE kit. Their detection resulted in a change in phenotype prediction in a high percentage (92%) of cases where a duplication call was made.
Furthermore, phenotype changed in 100% of rarer cases where a single CYP2D7-2D6 gene was present in our samples.
CYP2D6-2D7
genes must also be specifically tested for to be detected but they have no effect upon phenotype prediction because they were found in tandem with CYP2D6*4 and CYP2D6*10
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were described as were two new alleles, CYP2D6*13G1 and CYP2D6*13G2, and two variations of the CYP2D6*13A1 allele.
The information presented here is crucial for detection of hybrid genes regardless of the platform used to genotype CYP2D6. Probe sets for microarray detection must be designed with knowledge of hybrid genes or probes will not bind in a fashion that will allow their detection. In addition, CYP2D6 full gene sequencing and high throughput genotyping using next generation DNA analyzers will need to use the DNA sequences and genomic structures presented here as scaffolds for interpretation of sequence results.
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Amplicon K (Lane 6 and 7) primed from the CYP2D6 exon 9 sequence in CYP2D6*13B to the
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This occurred due to limitations of the CYP2D6 kit v1. Subsequent testing was done by CYP2D6 kit v2 which does detect This table shows the frequency in which a predicted duplicated allele was found to have a CYP2D7-2D6 + CYP2D6 arrangement. Star alleles predicted to be duplicated using the CYP2D6 ASPE kits are shown in column 1.
